Filtered By:
Condition: Thrombosis
Countries: Canada Health

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 79 results found since Jan 2013.

Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified
Publication date: November 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 11Author(s): Jason G. Andrade, Marc W. Deyell, Graham C. Wong, Laurent MacleAbstractAtrial fibrillation (AF) is a progressive chronic disease characterized by exacerbations and periods of remission. It is estimated that up to 20% to 30% of those with AF also have coronary artery disease (CAD), and 5% to 15% will require percutaneous coronary intervention (PCI). In patients with concomitant AF and CAD, management remains challenging and requires a careful and balanced assessment of the risk of bleeding against the anticipated impact on i...
Source: Canadian Journal of Cardiology - November 6, 2018 Category: Cardiology Source Type: research

E-034 EndoVascular treatment of wide-neck aneurysms, an evaluation of safety and effectiveness of stryker surpass evolve™ flow diverter system
ConclusionThe EVOLVE prospective, multicenter, single arm, pre-market study (ClinicalTrials.gov NCT: NCT04195568), is designed to evaluate the safety, efficacy, and performance of the Surpass EVOLVE Flow Diverter System in the treatment of unruptured wide-neck, saccular or fusiform IA located in the ICA and its branches with an RVD of 2.5 to 5.0 mm.Disclosures A. Arthur: 2; C; Stryker Neurovascular. J. Fifi: 1; C; Stryker Neurovascular. 2; C; Stryker Neurovascular. H. Rice: 2; C; Stryker Neurovascular. A. Wakhloo: 2; C; Stryker Neurovascular. A. Coon: 2; C; Stryker Neurovascular. V. Pereira: 2; C; Stryker, Medtronic, Balt, Cerenovus.
Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Arthur, A., Fifi, J., Rice, H., Wakhloo, A., Coon, A., Pereira, V. Tags: Electronic poster abstracts Source Type: research

Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study
Conclusions Our estimated background rates help contextualise observed events of these potential adverse events of special interest and to detect potential safety signals related to COVID-19 vaccines.
Source: BMJ Open - December 17, 2021 Category: General Medicine Authors: Nasreen, S., Calzavara, A. J., Sundaram, M. E., MacDonald, S. E., Righolt, C. H., Pai, M., Field, T. S., Zhou, L. W., Wilson, S. E., Kwong, J. C. Tags: Open access, Public health, COVID-19 Source Type: research

Multiple thromboembolic events from a left atrial appendage occlusion device
We report a clinico-pathological case where thrombus adherent to an incompletely endothelialized Watchman® device resulted in multiple thromboembolic events, contributing to a fatal outcome. This case illustrates uncertainties regarding the device’s endothelialization process. Teaser Left atrial appendage occlusion devices are an alternative to oral anticoagulation in patients with nonvalvular atrial fibrillation at risk of ischemic stroke. Post-implantation thromboprophylaxis is recommended, but the optimal regimen is unknown. We report a clinico-pathological case where thrombus adherent to an incompletely endotheliali...
Source: Canadian Journal of Cardiology - December 27, 2017 Category: Cardiology Source Type: research

Thrombotic and Bleeding Outcomes Following Perioperative Interruption of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation - a Comparative Analysis
Conclusions: The perioperative interruption of warfarin was associated with a higher 30-day rate of major bleeding as compared with DOAC interruption. Re-initiation of warfarin should be done judiciously following high bleeding risk procedures, and close INR monitoring may be warranted.DisclosuresShaw: Portola Pharmaceuticals: Research Funding. Douketis: Janssen: Consultancy; Pfizer: Other: Advisory Board; Boehringer-Ingelheim: Consultancy, Other: Advisory Board, Research Funding; Portola: Other: Advisory Board; The Medicines Company: Other: Advisory Board; Daiichi-Sankyo: Other: Advisory Board; Biotie: Other: Advisory Boa...
Source: Blood - November 21, 2018 Category: Hematology Authors: Shaw, J. R., Zhang, T., Le Gal, G., Douketis, J., Carrier, M. Tags: 332. Antithrombotic Therapy: Poster I Source Type: research

Peri-Device Leak after Left Atrial Appendage Closure: Incidence, Risk Factors and Clinical Impact
ConclusionsPDL rate detected by CCTA after LAAC is high, especially in cases with low device compression ratio (<10%), but decreased over time. The incidence of MACE was quantitatively greater with PDL, but the difference was not statistically significant. Larger studies are needed to determine the clinical importance of PDL.
Source: Canadian Journal of Cardiology - December 21, 2018 Category: Cardiology Source Type: research

Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis.
CONCLUSION: Administration of ESA and iron therapy reduced the risk for RBC transfusion compared with iron therapy alone in patients undergoing cardiac and non-cardiac surgery. Nevertheless, publication bias and heterogeneity reduces the confidence of the finding. Although the analysis was probably under-powered for some outcomes, no difference in the incidence of serious adverse events was observed with ESA and iron compared with iron alone. Further large prospective trials are required to confirm these findings. PMID: 30924000 [PubMed - as supplied by publisher]
Source: Canadian Journal of Anaesthesia - March 27, 2019 Category: Anesthesiology Authors: Kei T, Mistry N, Curley G, Pavenski K, Shehata N, Tanzini RM, Gauthier MF, Thorpe K, Schweizer TA, Ward S, Mazer CD, Hare GMT Tags: Can J Anaesth Source Type: research

Peridevice Leak After Left Atrial Appendage Closure: Incidence, Risk Factors, and Clinical Impact
ConclusionsThe PDL rate detected by CCTA after LAAC was high, especially in cases with a low device compression ratio (< 10%), but decreased over time. The incidence of MACE was quantitatively greater with PDL, but the difference was not statistically significant. Larger studies are needed to determine the clinical importance of PDL.RésuméIntroductionPeu d’études ont fait état des taux et des répercussions cliniques des fuites périprothétiques (FPP) après la fermeture de l’appendice auriculaire gauche (AAG) par voie percutanée.MéthodesNous avons inscrit de manière prospective tous les patients consécuti...
Source: Canadian Journal of Cardiology - March 30, 2019 Category: Cardiology Source Type: research

Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis
ConclusionAdministration of ESA and iron therapy reduced the risk for RBC transfusion compared with iron therapy alone in patients undergoing cardiac and non-cardiac surgery. Nevertheless, publication bias and heterogeneity reduces the confidence of the finding. Although the analysis was probably under-powered for some outcomes, no difference in the incidence of serious adverse events was observed with ESA and iron compared with iron alone. Further large prospective trials are required to confirm these findings.
Source: Canadian Journal of Anesthesia - May 8, 2019 Category: Anesthesiology Source Type: research

Periprocedural Anticoagulation for Cardioversion of Acute Onset Atrial Fibrillation and Flutter: Evidence Base for Current Guidelines
Publication date: Available online 12 June 2019Source: Canadian Journal of CardiologyAuthor(s): Jason G. Andrade, L. Brent MitchellABSTRACTThe practice of electrical or pharmacological cardioversion (CV) to restore sinus rhythm in patents with symptomatic atrial fibrillation (AF) or atrial flutter (AFL) has been a part of clinical practice for over 100 years. For almost as long as CV has been performed, it has been recognised that the act of restoring sinus rhythm is associated with an increased risk of stroke and systemic embolism, and that oral anticoagulation (OAC) therapy can be used to prevent peri-CV thromboembolism....
Source: Canadian Journal of Cardiology - June 13, 2019 Category: Cardiology Source Type: research

Anticoagulation in Patients with Advanced Chronic Kidney Disease: Walking the Fine Line between Benefit and Harm
Publication date: Available online 11 July 2019Source: Canadian Journal of CardiologyAuthor(s): Januvi Jegatheswaran, Gregory L. Hundemer, David Massicotte-Azarniouch, Manish M. SoodAbstractChronic kidney disease affects over 3 million Canadians and is highly associated with cardiovascular diseases that require anticoagulation, such as atrial fibrillation and venous thromboembolism. Patients with chronic kidney disease are at a problematic crossroads; they are at high risk of both thrombotic conditions requiring anticoagulation and bleeding complications due to anticoagulation. The limited high-quality clinical evidence to...
Source: Canadian Journal of Cardiology - July 12, 2019 Category: Cardiology Source Type: research

Trends in Anticoagulant Use at Nursing Home Admission and Variation by Frailty and Chronic Kidney Disease Among Older Adults with Atrial Fibrillation
ConclusionsWhile the proportion of residents with AF receiving oral anticoagulants at admission increased following the approval of DOACs, over 40% remained untreated. Among those treated, use of a DOAC increased, while warfarin use declined. The impact of these recent treatment patterns on the balance between benefit and harm among residents warrant further investigation.
Source: Drugs and Aging - April 21, 2021 Category: Geriatrics Source Type: research

Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research

COVID-19 and the Cardiovascular System: Insights into Effects and Treatments
Can J Physiol Pharmacol. 2021 Sep 21. doi: 10.1139/cjpp-2021-0093. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), an acute and highly transmissible infectious disease has reached a pandemic level since March 11, 2020 and continues to challenge the healthcare system worldwide. The pathogenesis of COVID-19 is a complex process involving mechanisms that suppress the host antiviral and innate immune response, while triggering marked activation of coagulation and hyperinflammation leading to cytokine storm in severe COVID-19. This review summarizes current evidence related to COVID-19-associated cardiovascul...
Source: Canadian Journal of Physiology and Pharmacology - September 21, 2021 Category: Drugs & Pharmacology Authors: Joey-Bahige Chammas Dylan Delaney Naim Chabaytah Sarah Abdulkarim Adel Schwertani Source Type: research